within Pharmacolibrary.Drugs.ATC.D;

model D01AC11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D01AC11</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxiconazole is a synthetic imidazole antifungal agent, primarily used topically to treat skin fungal infections such as athlete's foot, jock itch, and ringworm. It inhibits the biosynthesis of ergosterol, an essential component of fungal cell membranes. Approved for topical human use in several countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic parameters are available. Oxiconazole is intended mainly for topical use and systemic absorption is minimal.</p><h4>References</h4><ol><li><p>Kaul, G, et al., &amp; Chopra, S (2023). Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus . <i>Microbiology spectrum</i> 11(4) e0503122–None. DOI:<a href=\"https://doi.org/10.1128/spectrum.05031-22\">10.1128/spectrum.05031-22</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37428033/\">https://pubmed.ncbi.nlm.nih.gov/37428033</a></p></li><li><p>Mahmoud, RA, et al., &amp; Mansour, HF (2020). Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel. <i>Drug development and industrial pharmacy</i> 46(5) 706–716. DOI:<a href=\"https://doi.org/10.1080/03639045.2020.1752707\">10.1080/03639045.2020.1752707</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32266837/\">https://pubmed.ncbi.nlm.nih.gov/32266837</a></p></li><li><p>McClellan, KJ, et al., &amp; Markham, A (1999). Terbinafine. An update of its use in superficial mycoses. <i>Drugs</i> 58(1) 179–202. DOI:<a href=\"https://doi.org/10.2165/00003495-199958010-00018\">10.2165/00003495-199958010-00018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10439936/\">https://pubmed.ncbi.nlm.nih.gov/10439936</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D01AC11;
